DGAP-Adhoc 390 0 Kommentare Changes in the BRAIN Management Board

B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Change of Personnel

23.09.2016 17:53

Disclosure of an inside information according to Article 17 MAR,
transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

AD HOC RELEASE

Changes in the BRAIN Management Board

Zwingenberg, September 23, 2016: The Supervisory Board of BRAIN AG (ISIN
DE0005203947 / WKN 520394) today decided to appoint Frank Goebel, since
February 2015 Managing Director of B.R.A.I.N. Capital GmbH, to the
Management Board of BRAIN AG. This decision was taken upon a written
request from COO Eric Marks, which he handed over to the Chairman of the
Supervisory Board in advance of today's board meeting, and where he asked
to end his mandate before its expiration in October 2018.

Taking this into account, the Supervisory Board has taken the following
decisions in today's Supervisory Board meeting:

1) Frank Goebel will be appointed to the Executive Board of BRAIN AG,
starting from November 1, 2016. He will take over the responsibility for
the subsidiaries from Eric Marks. The CEO Dr Juergen Eck will be
responsible for the remaining tasks of Eric Marks.

2) Eric Marks will leave the Management Board as of October 31, 2016.

3) The Management Board appointment of Dr Georg Kellinghusen, which expires
on December 31, 2016, has been extended until the end of the ordinary
Annual General Meeting held in March 2017.

4) After the 2017 Annual General Meeting, Frank Goebel will additionally
assume the CFO responsibilities of Dr Georg Kellinghusen. As from that date
and until further notice, the BRAIN AG shall be led by a two-member
Executive Board.

+++ENDS+++

---------------------------------------------------------------------------

Information and Explanation of the Issuer to this News:

About BRAIN

BRAIN is one of Europe's leading technology companies in the field of
industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN
identifies previously untapped, efficient enzymes, microbial producer
organisms or natural substances from complex biological systems that can be
put to industrial use. The innovative solutions and products developed by
help of this 'Toolbox of Nature' are successfully applied in the chemistry,
the cosmetics and the food industries. Today, BRAIN's business model is
based on two pillars - 'BioScience' and 'BioIndustrial'. The first pillar,
'BioScience', comprises its - frequently exclusive - collaboration business
with industrial partners. The second pillar 'BioIndustrial' comprises the
development and commercialisation of BRAIN's own products and active
product components. Further information is available at www.brain-
biotech.de/en

23.09.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: ir@brain-biotech.de
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart,
Tradegate Exchange

End of Announcement DGAP News-Service

---------------------------------------------------------------------------